HSP90AB1 and cancer: Considering that geldanamycin analogs, which are HSP90 inhibitors, often cause dose-limiting hepatotoxicity, using HSP90 inhibition with these drugs may not be a suitable treatment option for this type of cancer (Pearl et al., 2008).